Journal article
Health-related quality of life and functional outcomes from a randomized-withdrawal study of long-term lisdexamfetamine dimesylate treatment in children and adolescents with attention-deficit/hyperactivity disorder
T Banaschewski, M Johnson, M Lecendreux, A Zuddas, B Adeyi, P Hodgkins, LA Squires, DR Coghill
CNS Drugs | ADIS INT LTD | Published : 2014
Abstract
Background: The stimulant prodrug lisdexamfetamine dimesylate (LDX) is an effective and generally well tolerated treatment for the symptoms of attention-deficit/hyperactivity disorder (ADHD). Positive impacts of LDX on health-related quality of life and functional impairment have previously been demonstrated in a 7-week, randomized, double-blind, placebo-controlled, phase III study in children and adolescents in Europe. Maintenance of these broad benefits, as well as symptomatic control, is a key goal of long-term management of ADHD.Objective: Secondary objectives of this multinational study in children and adolescents with ADHD were to assess the long-term maintenance of effectiveness of LD..
View full abstractGrants
Funding Acknowledgements
[ "This study was funded by Shire Development LLC. Shire develops and markets drugs to treat psychiatric disorders, including ADHD.", "The following authors have received compensation for serving as consultants or speakers, or they, or the institutions they work for, have received research support or royalties from the companies or organizations indicated: T. Banaschewski (Hexal, Lilly, Medice, Novartis, Otsuka, Oxford Outcomes, PCM Scientific, Shire and Vifor Pharma); M. Lecendreux (Shire, UCB and Vifor Pharma); M. Johnson (Janssen, Lilly, Otsuka, PCM Scientific, Shire, Vifor Pharma, and WM Lundgrens Research Fund); A. Zuddas (AstraZeneca, Bristol-Myers Squibb/Otsuka, Lilly, Lundbeck, Shire and Vifor Pharma); D. Coghill (Flynn, Janssen-Cilag, Lilly, Medice, Novartis, Otsuka, Oxford University Press, Pfizer, Schering-Plough, Shire, UCB and Vifor Pharma). B. Adeyi and L. A. Squires are employees of Shire, and may hold Shire stock and/or stock options. P. Hodgkins is a current employee of Vertex Pharmaceuticals and a former employee of Shire." ]